Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.
Jin, L., Pandey, P., Babine, R.E., Weaver, D.T., Abdel-Meguid, S.S., Strickler, J.E.(2005) Acta Crystallogr D Biol Crystallogr 61: 1418-1425
- PubMed: 16204896 
- DOI: 10.1107/S0907444905024340
- Primary Citation of Related Structures:  
1ZHM, 1ZHP, 1ZHR - PubMed Abstract: 
Activated factor XI (FXIa) is a key enzyme in the amplification phase of the blood-coagulation cascade. Thus, a selective FXIa inhibitor may have lesser bleeding liabilities and provide a safe alternative for antithrombosis therapy to available drugs on the market ...